Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors
Makaleler > Tam Makale · 2025
Yazarlar: Fatma Pinar Açar, Caner ACAR, Haydar Çağatay Yüksel, Gökhan Şahin, Burçak Karaca
Expert Review of Anticancer Therapy, Uluslararası, Wos, 2025, cilt 26, ss 639-648
DOI: 10.1080/14737140.2025.2602806
Özet
BACKGROUND: Hyperferritinaemia is common in cancer and may reflect tumor-associated macrophage activity and ferroptosis resistance, yet its prognostic value during immune checkpoint inhibitor (ICI) therapy is uncertain. METHODS: We retrospectively analyzed 262 patients with metastatic solid tumors treated with ICIs (January 2015-September 2024). An optimal serum ferritin (SF) cutoff stratified patients into low (<500 ng/mL) vs high (>500 ng/mL) groups. Outcomes were compared between SF groups, and SF was compared with other inflammatory markers - the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and C-reactive protein (CRP). RESULTS: = 0.035). Across metrics, SF showed the highest C-indices and superior 12-, 24-, and 36-month OS area under the curve (AUC) values compared with NLR, PLR, LMR, and CRP. CONCLUSIONS: Pretreatment hyperferritinaemia is an inexpensive, readily available biomarker that outperforms conventional inflammatory indices in predicting poor survival and diminished ICI benefit across diverse metastatic solid tumors.